From HAE Peru (Asociación de Pacientes con Angioedema Hereditario del Perú):
From Peru we want to inform you a brief summary of the most significant advances in favor of patients with HAE:
- In June of this year, after more than two years of having obtained the sanitary registration granted by the General Directorate of Medicines, Supplies and Drugs (DIGEMID), it was possible to apply, for the first time in Peru, Ecallantide (Kalbitor) for an acute HAE crisis.
- Since July of this year we have two ACARE reference centers, the only Peruvian specialized centers internationally recognized by the HAE International and Global Allergy and Asthma European Network (GA²LEN) to treat patients with HAE. You will find their contact information at https://haei.org/hae-member-countries/peru.
- Currently, the Peruvian Society of Allergy, Asthma and Immunology (SPAAI) has prepared a guide for the management of HAE, which is in the process of being published.
We leave you the links in which we share the news at the respective moment >> https://bit.ly/2Z3PcGn and https://bit.ly/3lO0LLC.
